Archives: 2021-11-04

The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions. Ethical issues and misinformation linked to overhyped science.

In March 2021, 1,480 U.S. businesses operating 2,754 clinics were found selling purported stem cell treatments for various indications. More than four times as many businesses than were identified 5 years ago are selling stem cell products that are not FDA-approved and lack convincing evidence of safety and efficacy following a new paper published in Cell

Read More


Children Hospital of Philadelphia Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers

In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches,

Read More


A review on Mesenchymal stem cells-derived exosomes for drug delivery

Mesenchymal stem cells (MSCs) are multi-functional stem cells that are present in multiple human tissues and can be found in the spinal cord, umbilical cord blood, umbilical cord tissue, placenta tissue, adipose tissue, etc.. With low immunogenicity, multi-directional diferentiation ability, in particular homing ability, MSCs have signifcant research potential in cardiovascular diseases, nervous diseases, and

Read More


Stem cell treatment failed to reduce inflammation in Multiple Sclerosis

Treatment with mesenchymal stem cells (MSCs) has failed to significantly reduce inflammation in the brain of adults with multiple sclerosis (MS) in a phase 2 clinical trial. The into-the-vein treatment also failed to improve other clinical aspects of the condition. The results were shared in a study titled “Safety, tolerability, and activity of mesenchymal stem cells versus placebo

Read More


New Knee Replacement device with “Smart Knee” Implant Enables Remote Patient Monitoring

Imagine knee replacement surgery with a “smart” implant that collects and transmits data enabling an orthopedic surgeon to monitor a patient’s recovery from afar. It became a reality this week when Peter Sculco, MD, and Fred Cushner, MD, orthopedic surgeons at Hospital for Special Surgery (HSS) performed the first knee replacement containing a smart sensor capable of

Read More


Serine protease inhibitor Nafamostat may be beneficial in the treatment of high-risk COVID-19 patients requiring oxygen treatment: results of a randomised Phase II clinical trial published in EClinical Medicine.

Nafamostat, a serine protease inhibitor, has been used for the treatment of disseminated intravascular coagulation and pancreatitis. In vitro studies and clinical reports suggest its beneficial effect in the treatment of COVID-19 pneumonia. This phase 2 open-label, randomised, multicentre, controlled trial evaluated nafamostat (4.8 mg/kg/day) plus standard-of-care (SOC) in hospitalised patients with COVID-19 pneumonia (i.e.,

Read More


Long-term persistence of SARS-CoV-2 neutralizing antibody responses after Covid-19 infection: levels conferring 50% protection are maintained for around 990 days post-symptom onset.

In a paper published on The lancet researchers of University of Hong Kong used 50% plaque reduction neutralization test (PRNT) antibody titre data from 115 sera collected longitudinally from 90 to 386 days after onset of symptoms or first RT-PCR confirmation from 62 RT–PCR confirmed SARS-CoV infected individuals, to estimate that PRNT antibody will remain

Read More